Therapeutic

Pipeline

Therapeutic

Pipeline

Therapeutic

Pipeline

RNA therapeutics in development across multiple indications.

Programs in Development

Strategic progression of RNA therapeutics across multiple indications.

Therapy Pipeline

Program

Stage

Approach

Cardiovascular

Lead Program

Fibroblast reprogramming for cardiac regeneration

Targeted microRNA delivery to convert cardiac myofibroblasts into functional cardiomyocyte-like cells, following myocardial infarction.

Preclinical (TRL 4)

Cardiovascular

Lead Program

Fibroblast reprogramming for cardiac regeneration

Targeted microRNA delivery to convert cardiac myofibroblasts into functional cardiomyocyte-like cells, following myocardial infarction.

Preclinical (TRL 4)

Cardiovascular

Lead Program

Fibroblast reprogramming for cardiac regeneration

Targeted microRNA delivery to convert cardiac myofibroblasts into functional cardiomyocyte-like cells, following myocardial infarction.

Preclinical (TRL 4)

Neuromuscular diseases

Muscle-targeted RNA delivery

Targeted RNA delivery for localized gene modulation in muscle tissue.

Research (TRL 3)

Neuromuscular diseases

Muscle-targeted RNA delivery

Targeted RNA delivery for localized gene modulation in muscle tissue.

Research (TRL 3)

Neuromuscular diseases

Muscle-targeted RNA delivery

Targeted RNA delivery for localized gene modulation in muscle tissue.

Research (TRL 3)

CAR-T Therapy

RNA delivery for engineerd T-Cell systems

Controlled RNA delivery to enhance engineered cell-based therapies.

Early research (TRL 2–3)

CAR-T Therapy

RNA delivery for engineerd T-Cell systems

Controlled RNA delivery to enhance engineered cell-based therapies.

Early research (TRL 2–3)

CAR-T Therapy

RNA delivery for engineerd T-Cell systems

Controlled RNA delivery to enhance engineered cell-based therapies.

Early research (TRL 2–3)

Program Cardiovascular

Our lead program targets myocardial infarction through direct reprogramming of cardiac fibroblasts into functional cardiomyocytes, using targeted RNA delivery to restore heart function.

Post-infarction scarring

Polymer-RNA conjugate

Fibroblast conversion

Functional recovery

Platform Performance

(validated in vivo in a myocardial infarction mouse model)

Higher Targeting

Extended Retention

Lower accumulation  in non target organs

+5.6

Functional Recovery

+5.6

Functional Recovery

up to 60

Fibrosis

up to 60

Fibrosis

Dot pattern image ready

Platform Potential

Our polymer delivery platform can be adapted across multiple therapeutic indications,

expanding our pipeline and partnership opportunities.

Dot pattern image ready

Neuromuscular

Muscle-specific targeting for kennedy's disease and other muscle related conditions

Neuromuscular

Muscle-specific targeting for kennedy's disease and other muscle related conditions

Neuromuscular

Muscle-specific targeting for kennedy's disease and other muscle related conditions

Dot pattern image ready

CAR-T Therapy

Targeted RNA delivery to immune cells to generate CAR-T cells in vivo

CAR-T Therapy

Targeted RNA delivery to immune cells to generate CAR-T cells in vivo

CAR-T Therapy

Targeted RNA delivery to immune cells to generate CAR-T cells in vivo

Explore the Technology

Dot pattern image ready

Partner with us to advance

RNA therapeutics

We are actively seeking pharmaceutical and research partners to accelerate the development of our RNA delivery platform and bring innovative therapeutics to patients.

Partner with us

Dot pattern image ready

Partner with us to advance RNA therapeutics

We are actively seeking pharmaceutical and research partners to accelerate the development of our RNA delivery platform and bring innovative therapeutics to patients.

Partner with us

Dot pattern image ready

Partner with us

to advance

RNA therapeutics

We are actively seeking pharmaceutical and research partners to accelerate the development of our RNA delivery platform and bring innovative therapeutics to patients.

Partner with us

Therapeutic

Pipeline

Therapeutic

Pipeline

Therapeutic

Pipeline

Programs in Development

Fibroblast reprogramming for cardiac regeneration

Fibroblast reprogramming for cardiac regeneration

Fibroblast reprogramming for cardiac regeneration

Muscle-targeted RNA delivery

Muscle-targeted RNA delivery

Muscle-targeted RNA delivery

RNA delivery for engineerd T-Cell systems

RNA delivery for engineerd T-Cell systems

RNA delivery for engineerd T-Cell systems

Program Cardiovascular

Post-infarction scarring

Post-infarction scarring

Post-infarction scarring

Polymer-RNA conjugate

Polymer-RNA conjugate

Polymer-RNA conjugate

Fibroblast conversion

Fibroblast conversion

Fibroblast conversion

Functional recovery

Functional recovery

Functional recovery

Platform Performance

Higher Targeting

Higher Targeting

Extended Retention

Extended Retention

Lower accumulation in non target organs

Lower accumulation in non target organs

Functional Recovery

Functional Recovery

Fibrosis

Fibrosis

Platform Potential

Neuromuscular

Neuromuscular

Neuromuscular

CAR-T Therapy

CAR-T Therapy

CAR-T Therapy

Lower accumulation  in non target organs

Lower accumulation  in non target organs